清肺合剂联合化疗治疗老年晚期非小细胞肺癌临床疗效观察

Clinical effect observation of Qingfei Mixture combined with chemotherapy of GP regimen in treating elderly patients with advanced non-small cell lung cancer

目的:观察清肺合剂联合化疗治疗老年晚期非小细胞肺癌(NSCLC)临床疗效。方法:选择2008年1月-2010年12月间收治的经确诊的初治晚期NSCLC患者73例,分别入清肺合剂联合GP方案化疗(治疗组)33例和单纯GP方案化疗(对照组)40例,入组患者至少接受2个周期以上的化疗。结果:入组的73例患者均可评价疗效,治疗1年后随访,治疗组33例,对照组37例,失访3例。治疗组和对照组总有效率分别是33.33%和20.00%,中位生存期为16.6个月和15.1个月,1年生存率为75.76%和59.46%,2年生存率为18.18%和16.22%,两组差异无统计学意义。治疗后,治疗组在KPS评分、临床症状改善及化疗毒副作用方面均优于对照组(P<0.05)。结论:清肺合剂联合化疗治疗老年晚期非小细胞肺癌,在改善患者的临床症状,提高患者的生活质量,减轻化疗的毒副反应等方面具有临床意义。

Objective： To observe the effects of Qingfei Mixture in association with chemotherapy in curing elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods： 73 elderly patients with confimed diagnosis of advanced non-small cell lung cancer between January 2008 and December 2010, were assigned to treatment group （Qingfei Mixture treatment combined with chemotherepy of GP regimen, n=33） and control group （chemotherepy of GP regimen, n=40）, all eligible patients received two cycles chemotherapy at least. Results： 73 patients were evaluable for efficacy. The effective rate was 33.33% vs 20.00% in the treatment group and the control group respectively, median overal survival （OS） was 16.6 months vs 15.1 months, 1-year survival was 75.76% vs 59.46%, 2-year survival was 18.18% vs 16.22%, but there were no significant differences between two groups. However, the KPS score, clinical symptom improvement and chemotherapy toxicity in the treatment group had statistical significance differences compared with the control group （P〈0.05）. Conclusion： Qingfei Mixture can improve clinical symptoms, enhance the quality of life, and relieve side and toxic effects in treating elderly patients with advanced NSCLC.